Eupraxia Pharmaceuticals (EPRX) Bloom Burton & Co. Healthcare Investor Conference 2026 summary

Key program updates and data

• Presented fresh data from ongoing clinical trials, highlighting a pivotal year with multiple catalysts and new programs expected to generate significant results throughout the year.

• Well-capitalized to fund operations and clinical development through mid-2028, with recent financing and warrant exercises boosting cash reserves to $143 million.

• Lead technology, DiffuSpheres, enables local, sustained drug delivery, focusing on fluticasone propionate for eosinophilic esophagitis (EoE) and other GI indications.

• Patent coverage extends into the 2040s, supporting long-term commercial potential.

• Management and board have significant ownership, aligning interests with investors and patients.

Clinical trial results and pipeline expansion

• Phase IIa RESOLVE trial shows rapid and durable clinical remission in EoE: 40% at 2 weeks, 60% at 12 weeks, and ~80% at 24 weeks, with durability to 52 weeks.

• Histology data demonstrate dose-dependent reversal of inflammation and fibrosis, with up to 90% improvement at higher doses.

• No drug-related serious adverse events; no cases of oropharyngeal candidiasis, and only mild, transient sore throat reported.

• Phase IIb trial is ongoing, with interim analysis expected in late Q4 2024 to inform phase III design; phase III targeted for mid-2027.

• Expansion into benign esophageal strictures (trial launch in 2026) and fibrostenotic Crohn’s disease (trial launch in 2027) planned, leveraging same technology and commercial infrastructure.

Market opportunity and commercial strategy

• EoE prevalence now estimated at up to one million in the US, with significant unmet need due to limitations of current therapies.

• Approved competitors are expensive ($22,000–$109,000/year) and limited in duration or efficacy, creating a large opportunity for a durable, once-yearly therapy.

• Addressable market for benign esophageal strictures is several hundred thousand patients, and for fibrostenotic Crohn’s, a few hundred thousand, with potential for franchise expansion.

• Commercial strategy leverages overlap in prescribers and delivery methods across GI indications.

• Future pipeline may extend technology to oncology and CNS indications.